Starry-Sky Projection and Maternal Voice for Sleep After Pediatric Cardiac Surgery
Effects of Starry-Sky Projection and Maternal Voice on Postoperative Sleep in Children Undergoing Cardiac Surgery: A 2 × 2 Factorial Randomized Controlled Trial
The goal of this clinical trial is to determine whether a starry-sky projection affects sleep during the early period after cardiac surgery in young children. The main question it aims to answer is:
• Does a starry-sky projection improve how well children sleep during the first three nights after surgery compared with routine nighttime lighting? The study will also explore whether sleep outcomes differ between children who listen to their mother's recorded voice and those who listen to an unfamiliar woman's recorded voice, and whether the effect of the starry-sky projection differs depending on the type of voice.
Children aged 6 months to 6 years will be randomly assigned to one of four combinations of visual and sound conditions. They will:
- Receive either a starry-sky projection or routine nighttime lighting
- Listen to either their mother's recorded voice or an unfamiliar woman's recorded voice
- Have their sleep monitored during the first three nights after surgery using a contactless device placed under the pillow that does not require sensors attached to the child.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Biyu Shen, PhD
- Número de teléfono: +86 13862937317
- Correo electrónico: shenbiyu@126.com
Ubicaciones de estudio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200127
- Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
-
Contacto:
- Biyu Shen, PhD
- Número de teléfono: +86 13862937317
- Correo electrónico: shenbiyu@126.com
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- A confirmed diagnosis of congenital heart disease.
- Age between 6 months and 6 years.
- Scheduled to undergo their first elective open-heart surgery.
- An anticipated postoperative stay in the cardiac intensive care unit (CICU) of at least 48 hours.
- Written informed consent provided by a parent or legal guardian.
Exclusion Criteria:
- Epilepsy or another severe neurological disorder.
- A severe psychiatric disorder.
- Hearing impairment that interferes with the perception of auditory stimuli.
- Visual impairment that interferes with the perception of visual stimuli.
- Malformations of other organs or pre-existing severe comorbidities.
- A history of chronic pain.
- A previously diagnosed sleep disorder.
- Endotracheal tube could not be successfully removed before 7 p.m. on the day of surgery.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación factorial
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Starry-Sky Projection + Maternal Voice
|
A starry-sky projector will display gently moving, diffuse star-like points on the ceiling, avoiding direct light exposure to the child's eyes. Settings will remain constant, without rapid movement, frequent colour changes, or visible flicker. Built-in audio will be disabled. Sessions will last 30 minutes before anticipated sleep onset on postoperative nights 0-2. A personalised recording from the child's mother containing the child's name, reassuring and sleep-related phrases, and a familiar lullaby or gentle melody will be played for 30 minutes before anticipated sleep onset. The recording will be played using a speaker positioned approximately 20 cm from the child's ear, with sound intensity maintained at 45-50 dB. |
|
Experimental: Starry-Sky Projection + Unfamiliar Female Voice
|
A starry-sky projector will display gently moving, diffuse star-like points on the ceiling, avoiding direct light exposure to the child's eyes. Settings will remain constant, without rapid movement, frequent colour changes, or visible flicker. Built-in audio will be disabled. Sessions will last 30 minutes before anticipated sleep onset on postoperative nights 0-2. A standardized recording by an unfamiliar adult woman who is not involved in the child's clinical care will be played for 30 minutes before anticipated sleep onset. The recording will contain generic reassuring and sleep-related phrases and a gentle lullaby or nursery rhyme. Playback duration, speaker placement, and sound intensity will be identical to the maternal voice condition. |
|
Comparador activo: Conventional Lighting + Maternal Voice
|
A personalised recording from the child's mother containing the child's name, reassuring and sleep-related phrases, and a familiar lullaby or gentle melody will be played for 30 minutes before anticipated sleep onset. The recording will be played using a speaker positioned approximately 20 cm from the child's ear, with sound intensity maintained at 45-50 dB. Participants will remain under routine nocturnal lighting in the CICU or general ward without additional projection. |
|
Comparador activo: Conventional Lighting + Unfamiliar Female Voice
|
A standardized recording by an unfamiliar adult woman who is not involved in the child's clinical care will be played for 30 minutes before anticipated sleep onset. The recording will contain generic reassuring and sleep-related phrases and a gentle lullaby or nursery rhyme. Playback duration, speaker placement, and sound intensity will be identical to the maternal voice condition. Participants will remain under routine nocturnal lighting in the CICU or general ward without additional projection. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sleep Efficiency
Periodo de tiempo: Postoperative nights 0, 1, and 2
|
Sleep efficiency is defined as the percentage of total sleep time (TST) relative to time in bed (TIB) during the sleep-related nocturnal interval. TIB refers to the interval from the start of an attempt to sleep until the end of the nocturnal sleep opportunity and includes sleep onset latency and intervening wakefulness. Sleep efficiency will be assessed using a contactless ballistocardiography (BCG)-based sleep monitoring mat during postoperative nights 0-2. The mean sleep efficiency across the three postoperative nights will be used as the primary outcome measure. Higher values indicate better sleep efficiency. |
Postoperative nights 0, 1, and 2
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total Sleep Time
Periodo de tiempo: Postoperative nights 0, 1, and 2
|
Total sleep time during the nocturnal monitoring period, measured using a contactless sleep monitoring mat. |
Postoperative nights 0, 1, and 2
|
|
Sleep-Onset Latency
Periodo de tiempo: Postoperative nights 0, 1, and 2
|
Time from the beginning of the nocturnal sleep monitoring period to sleep onset, measured using a contactless sleep monitoring mat. |
Postoperative nights 0, 1, and 2
|
|
Wake After Sleep Onset
Periodo de tiempo: Postoperative nights 0, 1, and 2
|
Total duration of wakefulness occurring after sleep onset during the nocturnal monitoring period, measured using a contactless sleep monitoring mat. |
Postoperative nights 0, 1, and 2
|
|
Sleep Fragmentation Index
Periodo de tiempo: Postoperative nights 0, 1, and 2
|
Sleep fragmentation index derived from the contactless sleep monitoring mat, reflecting the degree of sleep disruption during the nocturnal monitoring period. |
Postoperative nights 0, 1, and 2
|
|
Sleep-Stage Distribution
Periodo de tiempo: Postoperative nights 0, 1, and 2
|
Estimated distribution of sleep stages during the nocturnal monitoring period, expressed as the proportion of total sleep time and measured using a contactless sleep monitoring mat. |
Postoperative nights 0, 1, and 2
|
|
Incidence of Postoperative Delirium
Periodo de tiempo: Postoperative night 0 through postoperative day 2
|
Postoperative delirium will be assessed using the Cornell Assessment of Pediatric Delirium (CAPD). A total CAPD score ≥9 will indicate a positive delirium screen. Assessments will be performed every 12 hours. |
Postoperative night 0 through postoperative day 2
|
|
Richmond Agitation-Sedation Scale Score
Periodo de tiempo: Postoperative night 0 through postoperative day 2
|
Sedation and agitation will be assessed using the Richmond Agitation-Sedation Scale (RASS). Scores range from -5 to +4, with lower scores indicating deeper sedation and higher scores indicating greater agitation. Assessments will be performed every 4 hours. |
Postoperative night 0 through postoperative day 2
|
|
Pain Score
Periodo de tiempo: Postoperative night 0 through postoperative day 2
|
Postoperative pain will be assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale. Scores range from 0 to 10, with higher scores indicating greater pain severity. Assessments will be performed every 4 hours. |
Postoperative night 0 through postoperative day 2
|
|
Postoperative Sedative Exposure
Periodo de tiempo: Postoperative day 0 through postoperative day 2
|
Administration of dexmedetomidine and other sedative medications will be recorded to characterize postoperative sedative exposure. |
Postoperative day 0 through postoperative day 2
|
|
Postoperative Analgesic Exposure
Periodo de tiempo: Postoperative day 0 through postoperative day 2
|
Administration of sufentanil and other analgesic medications will be recorded to characterize postoperative analgesic exposure. |
Postoperative day 0 through postoperative day 2
|
|
Postoperative Vasoactive Medication Exposure
Periodo de tiempo: Postoperative day 0 through postoperative day 2
|
Administration of dopamine and other vasoactive medications will be recorded to characterize postoperative vasoactive medication exposure. |
Postoperative day 0 through postoperative day 2
|
|
Heart Rate Variability
Periodo de tiempo: Postoperative nights 0, 1, and 2
|
Heart rate variability will be continuously measured using the 5S Sleep Tracking Mat as an objective indicator of autonomic regulation. |
Postoperative nights 0, 1, and 2
|
|
CICU Length of Stay
Periodo de tiempo: Measured in days admitted to the CICU, an average of 2 days
|
Cardiac intensive care unit (CICU) length of stay will be calculated from postoperative CICU admission to CICU discharge. |
Measured in days admitted to the CICU, an average of 2 days
|
|
Total Hospital Length of Stay
Periodo de tiempo: Measured in days admitted to the hospital, an average of 10 days.
|
Total hospital length of stay will be calculated as the number of days from hospital admission to hospital discharge. |
Measured in days admitted to the hospital, an average of 10 days.
|
|
Parental satisfaction
Periodo de tiempo: On the day of discharge, an average of 10 days
|
Parental satisfaction with the child's overall hospital care will be assessed using a 100-mm visual analogue scale (VAS), ranging from 0 mm ("very dissatisfied") to 100 mm ("very satisfied"). Higher scores indicate greater satisfaction. |
On the day of discharge, an average of 10 days
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- SCMCIRB-K2025331-1
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .